Roughly a month after suffering a setback in its oncology franchise with the market withdrawal of a drug for lung cancer, Takeda Pharmaceutical Co. Ltd. got some welcome news with the approval of a colorectal cancer medication that it licensed for more than $1bn from its China-based developer earlier this year.
The US Food and Drug Administration approved Fruzaqla (fruquintinib) on 8 November, ahead of its 30 November action date, for...







